Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer.
Evelyn WaughJuan GlinkaDaniel A BreadnerRachel Q Liu HennesseyEphraim S TangLaura AllenStephen WelchKen LeslieAnton SkaroPublished in: Annals of hepato-biliary-pancreatic surgery (2024)
We found a survival benefit of NAC with FOLFIRINOX for BRPC. Greater pre-treatment of CA19-9 and multivessel involvement on initial imaging were associated with progression of the disease following NAC.